Dynavax Technologies Corp., of Berkeley, Calif., reported third-quarter and nine-month sales of hepatitis B vaccine Heplisav-B totaling $1.5 million and $2.9 million, respectively. The drug was launched in the first quarter of this year. Dynavax posted a net loss of $40.5 million, or 65 cents per share, for the quarter. Cash, equivalents and marketable securities totaled $180.2 million as of Sept. 30. Shares of Dynavax (NASDAQ:DVAX) closed Tuesday at $11.65, up 53 cents. (See BioWorld, Nov. 13, 2017.)